Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation
Open Access
- 1 August 2008
- journal article
- Published by Elsevier BV
- Vol. 283 (35), 23721-23730
- https://doi.org/10.1074/jbc.m708360200
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 MimeticsPLoS Medicine, 2007
- BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR MutationsPLoS Medicine, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Cyclin D1: polymorphism, aberrant splicing and cancer riskOncogene, 2006
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Location, location, location: The role of cyclin D1 nuclear localization in cancerJournal of Cellular Biochemistry, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenograftsInternational Journal of Cancer, 2004
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor ReceptorPublished by Elsevier BV ,2002